GEMOX Regimen

Cross-source consensus on GEMOX Regimen from 1 sources and 4 claims.

1 sources · 4 claims

Uses

R0 resection in NEO-ERA-01 requires no visible tumor at the margin and no tumor cells within 1 mm microscopically. — Neoadjuvant hepatic arterial infusion chemotherapy (HAIC) with GEMOX and lenvatinib in combination with adebrelimab for resectable high-risk recurrent intrahepatic cholangiocarcinoma (ICC): study protocol of the NEO-ERA-01 feasibility trial
HAIC-GEMOX delivers gemcitabine and oxaliplatin at high local concentration directly to the tumor. — Neoadjuvant hepatic arterial infusion chemotherapy (HAIC) with GEMOX and lenvatinib in combination with adebrelimab for resectable high-risk recurrent intrahepatic cholangiocarcinoma (ICC): study protocol of the NEO-ERA-01 feasibility trial
Systemic chemotherapy is the first-line treatment for unresectable ICC and is also used in neoadjuvant settings. — Neoadjuvant hepatic arterial infusion chemotherapy (HAIC) with GEMOX and lenvatinib in combination with adebrelimab for resectable high-risk recurrent intrahepatic cholangiocarcinoma (ICC): study protocol of the NEO-ERA-01 feasibility trial
Gemcitabine plus cisplatin is the most widely adopted systemic chemotherapy regimen for ICC. — Neoadjuvant hepatic arterial infusion chemotherapy (HAIC) with GEMOX and lenvatinib in combination with adebrelimab for resectable high-risk recurrent intrahepatic cholangiocarcinoma (ICC): study protocol of the NEO-ERA-01 feasibility trial